Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has submitted to the U.S. Food and Drug Administrati
Read the full article here
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
